Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 8/2015

01-08-2015 | Hypertension and the Kidney (RM Carey, Section Editor)

Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review

Author: Ibrahim M. Salman

Published in: Current Hypertension Reports | Issue 8/2015

Login to get access

Abstract

Cardiovascular autonomic dysfunction is a major complication of chronic kidney disease (CKD), likely contributing to the high incidence of cardiovascular mortality in this patient population. In addition to adrenergic overdrive in affected individuals, clinical and experimental evidence now strongly indicates the presence of impaired reflex control of both sympathetic and parasympathetic outflow to the heart and vasculature. Although the principal underlying mechanisms are not completely understood, potential involvements of altered baroreceptor, cardiopulmonary, and chemoreceptor reflex function, along with factors including but not limited to increased renin–angiotensin–aldosterone system activity, activation of the renal afferents and cardiovascular structural remodeling have been suggested. This review therefore analyzes potential mechanisms underpinning autonomic imbalance in CKD, covers results accumulated thus far on cardiovascular autonomic function studies in clinical and experimental renal failure, discusses the role of current interventional and therapeutic strategies in ameliorating autonomic deficits associated with chronic renal dysfunction, and identifies gaps in our knowledge of neural mechanisms driving cardiovascular disease in CKD.
Literature
1.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70. doi:10.​1038/​ki.​2011.​368.PubMed
2.
Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol CJASN. 2009;4 Suppl 1:S5–11. doi:10.​2215/​cjn.​05980809.
3.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034–47. doi:10.​1681/​asn.​2005101085.PubMed
4.
U.S. renal data system. U.S. renal data system annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National institutes of health, national institute of diabetes and digestive and kidney diseases, Bethesda, MD2013 Jan. Report No.: 1523–6838 (Electronic) 0272–6386 (Linking).
5.
6.
Kidney disease outcomes quality initiative (KDOQI) clinical practice guideline for chronic kidney disease care [database on the Internet]. National kidney foundation http://​www.​kidney.​org/​. 2013. Accessed.
7.
8.
Morgado E, Neves PL. Hypertension and chronic kidney disease: cause and consequence—therapeutic considerations. In: Babaei H, editor. Antihypertensive drugs. Rijeka: InTech; 2012.
9.
10.•
Yao Y, Hildreth CM, Farnham MM, Saha M, Sun QJ, Pilowsky PM, et al. The effect of losartan on differential reflex control of sympathetic nerve activity in chronic kidney disease. J Hypertens. 2015. doi:10.​1097/​hjh.​0000000000000535​. This recent observational study assessed the role of the renin–angiotensin system in triggering differential reflex sympathetic responses in a rat model of CKD.
11.
Ameer OZ, Hildreth CM, Phillips JK. Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension. Physiol Rep 2014;2(11). doi:10.​14814/​phy2.​12205.
12.••
Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846–51. This well-executed clinical study demonstrated increases in SNA during the early stages of renal disease that contribute to further decline in GFR in patients with CKD.PubMed
13.••
Salman IM, Hildreth CM, Ameer OZ, Phillips JK. Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension. 2014;63(4):804–10. doi:10.​1161/​hypertensionaha.​113.​02110. This was the first study to provide a comprehensive investigation of mechanisms of altered baroreflex function in a rat model of CKD.PubMed
14.
Hildreth CM, Kandukuri DS, Goodchild AK, Phillips JK. Temporal development of baroreceptor dysfunction in a rodent model of chronic kidney disease. Clin Exp Pharmacol Physiol. 2013;40(7):458–65.PubMed
15.
Robinson TG, Carr SJ. Cardiovascular autonomic dysfunction in uremia. Kidney Int. 2002;62(6):1921–32.PubMed
16.
Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139(9):761–76.PubMed
17.
Ameer OZ, Salman IM, Avolio AP, Phillips JK, Butlin M. Opposing changes in thoracic and abdominal aortic biomechanical properties in rodent models of vascular calcification and hypertension. Am J Physiol Heart Circ Physiol. 2014. doi:10.​1152/​ajpheart.​00139.​2014.
18.
Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol. 2005;16(4):959–65. doi:10.​1681/​asn.​2004070582.PubMed
19.
20.
Pal GK, Pal P, Nanda N, Amudharaj D, Adithan C. Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives. Futur Cardiol. 2013;9(1):53–69. doi:10.​2217/​fca.​12.​80.
21.•
Dursun B, Demircioglu F, Varan HI, Basarici I, Kabukcu M, Ersoy F, et al. Effects of different dialysis modalities on cardiac autonomic dysfunctions in end-stage renal disease patients: one year prospective study. Ren Fail. 2004;26(1):35–8. This prospective clinical study not only demonstrated cardiac autonomic dysfunction in ESRD patients but also showed that continuous ambulatory peritoneal dialysis had a better effect on cardiac autonomic indices than hemodialysis.PubMed
22.
Ranpuria R, Hall M, Chan CT, Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant. 2008;23(2):444–9.PubMed
23.
24.
Johansson M, Gao SA, Friberg P, Annerstedt M, Carlstrom J, Ivarsson T, et al. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens. 2007;25(1):163–8.PubMed
25.
Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40(1):41–6.PubMed
26.
Converse Jr RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8.PubMed
27.
Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002;4(3):256–60.PubMed
28.
Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15(3):524–37.PubMed
29.
Neahring JC, Jones SY, DiBona GF. Cardiopulmonary baroreflex function in nephrotic rats. J Am Soc Nephrol. 1995;5(12):2082–6.PubMed
30.
Rassaf T, Schueller P, Westenfeld R, Floege J, Eickholt C, Hennersdorf M, et al. Peripheral chemosensor function is blunted in moderate to severe chronic kidney disease. Int J Cardiol. 2012;155(2):201–5.PubMed
31.
Tinucci T, Abrahao SB, Santello JL, Mion Jr D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens. 2001;15(6):401–6.PubMed
32.
Gattone 2nd VH, Siqueira Jr TM, Powell CR, Trambaugh CM, Lingeman JE, Shalhav AL. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med (Maywood, NJ). 2008;233(8):952–7. doi:10.​3181/​0802-rm-54.
33.
Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23(7):1250–7.PubMedCentralPubMed
34.••
Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214–20. doi:10.​1016/​j.​ijcard.​2013.​01.​218. This unique clinical study showed reductions in both BP and muscle SNA in renally denervated hypertensive patients with ESRD.PubMed
35.
Yildiz A, Sever MS, Demirel S, Akkaya V, Turk S, Turkmen A, et al. Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Nephron. 1998;80(1):57–60.PubMed
36.
Harris DC, Rangan GK. Retardation of kidney failure—applying principles to practice. Ann Acad Med Singap. 2005;34(1):16–23.PubMed
37.
Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14(2):425–30.PubMed
38.
Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int Suppl. 2003;84(200):S197–200.PubMed
39.
Kashihara N, Satoh M. Molecular pathogenesis of chronic kidney disease. Nihon Rinsho Jpn J Clin Med. 2008;66(9):1671–7.
40.
Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res Off J Jpn Soc Hypertens. 2010;33(6):521–8. doi:10.​1038/​hr.​2010.​35.
41.
Jeewandara TM, Ameer OZ, Boyd R, Wyse BF, Underwood CF, Phillips JK. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease. Clin Exp Pharmacol Physiol. 2015;42(4):353–60. doi:10.​1111/​1440-1681.​12372.PubMed
42.
Li Y-L. Cardiovascular autonomic dysfunction in diabetes as a complication: cellular and molecular mechanisms. In: Wagner D, editor. Type 1 diabetes complication. Rijeka: InTech; 2011.
43.
Rubinger D, Backenroth R, Sapoznikov D. Restoration of baroreflex function in patients with end-stage renal disease after renal transplantation. Nephrol Dial Transplant. 2009;24(4):1305–13. doi:10.​1093/​ndt/​gfn732.PubMed
44.
45.•
Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933–9. This excellent review summarizes the deleterious effects of SNS hyperactivity in CKD, as well as its possible underlying mechanisms.PubMed
46.
Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C. Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int. 1985;28(5):814–22.PubMed
47.
Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron. 1984;36(1):24–9.PubMed
48.
Phillips JK, Hopwood D, Loxley RA, Ghatora K, Coombes JD, Tan YS, et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press Res. 2007;30(3):129–44.PubMed
49.••
Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340(17):1321–8. This clinical study was one of the first to assess sympathetic baroreflex function in CKD patients.PubMed
50.
Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol (Bethesda, Md : 1985). 2008;105(6):1873–6. doi:10.​1152/​japplphysiol.​90849.​2008.
51.
52.
Sahin M, Kayatas M, Urun Y, Sennaroglu E, Akdur S. Performing only one cardiovascular reflex test has a high positive predictive value for diagnosing autonomic neuropathy in patients with chronic renal failure on hemodialysis. Ren Fail. 2006;28(5):383–7. doi:10.​1080/​0886022060068372​2.PubMed
53.
Lewanski R, Chrzanowski W. Assessment of autonomic nervous system by spectral analysis of heart rate and blood pressure in hemodialysed patients. Pol Merkur Lekarski Org Polskiego Towarz Lekarskiego. 2003;15(88):391–3.
54.
Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(11):1152–61. doi:10.​1016/​j.​jacc.​2011.​04.​041.PubMed
55.
Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol CJASN. 2011;6(11):2620–7. doi:10.​2215/​cjn.​06970711.
56.
Adamczak M, Zeier M, Dikow R, Ritz E. Kidney and hypertension. Kidney Int Suppl. 2002;80:62–7.PubMed
57.
58.
Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes. Circ Res. 2001;89(9):815–22.PubMed
59.
Raizada V, Hillerson D, Amaram JS, Skipper B. Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. J Investig Med Off Publ Am Fed Clin Res. 2012;60(5):785–91. doi:10.​231/​JIM.​0b013e318250b101​.
60.
Grisk O, Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res. 2004;61(2):238–46.PubMed
61.
62.
Guizar-Mendoza JM, Amador-Licona N, Lozada EE, Rodriguez L, Gutierrez-Navarro M, Dubey-Ortega LA, et al. Left ventricular mass and heart sympathetic activity after renal transplantation in children and young adults. Pediatr Nephrol. 2006;21(10):1413–8. doi:10.​1007/​s00467-006-0238-8.PubMed
63.
64.
Tory K, Horvath E, Suveges Z, Fekete A, Sallay P, Berta K, et al. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol. 2004;61(5):316–23.PubMed
65.
Agarwal A, Anand IS, Sakhuja V, Chugh KS. Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure. Kidney Int. 1991;40(3):489–95.PubMed
66.
de Ferrari GM, Vanoli E, Stramba-Badiale M, Hull Jr SS, Foreman RD, Schwartz PJ. Vagal reflexes and survival during acute myocardial ischemia in conscious dogs with healed myocardial infarction. Am J Physiol. 1991;261(1 Pt 2):H63–9.PubMed
67.
Di Rienzo M, Parati G, Castiglioni P, Tordi R, Mancia G, Pedotti A. Baroreflex effectiveness index: an additional measure of baroreflex control of heart rate in daily life. Am J Physiol Regul Integr Comp Physiol. 2001;280(3):R744–51.PubMed
68.
Johnson PL, Shekhar A. Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors. J Neurosci Off J Soc Neurosci. 2006;26(26):7093–104. doi:10.​1523/​jneurosci.​0408-06.​2006.
69.
Lacy P, Carr SJ, O'Brien D, Fentum B, Williams B, Paul SK, et al. Reduced glomerular filtration rate in pre-dialysis non-diabetic chronic kidney disease patients is associated with impaired baroreceptor sensitivity and reduced vascular compliance. Clin Sci (London, England : 1979). 2006;110(1):101–8. doi:10.​1042/​cs20050192.
70.
71.••
Salman IM, Phillips JK, Ameer OZ, Hildreth CM. Abnormal central control underlies impaired baroreflex control of heart rate and sympathetic nerve activity in female Lewis polycystic kidney rats. J Hypertens. 2015. This was the first observational study to provide a mechanistic explanation for baroreflex dysfunction in a female rat model of CKD.
72.
Merrill DC, Segar JL, McWeeny OJ, Robillard JE. Sympathetic responses to cardiopulmonary vagal afferent stimulation during development. Am J Physiol. 1999;277(4 Pt 2):H1311–6.PubMed
73.
74.
Grassi G, Parati G, Pomidossi G, Giannattasio C, Casadei R, Bolla GB, et al. Effects of haemodialysis and kidney transplantation on carotid and cardiopulmonary baroreflexes in uremic patients. J Hypertens. 1987;5 suppl 5:S367–9.
75.
Hinojosa-Laborde C, Jones SY, DiBona GF. Hemodynamics and baroreflex function in rats with nephrotic syndrome. Am J Physiol. 1994;267(4 Pt 2):R953–64.PubMed
76.
Daugirdas JT. Pathophysiology of dialysis hypotension: an update. Am J Kidney Dis. 2001;38(4 Suppl 4):S11–7.PubMed
77.
Rassaf T, Westenfeld R, Balzer J, Lauer T, Merx M, Floege J, et al. Modulation of peripheral chemoreflex by neurohumoral adaptations after kidney transplantation. Eur J Med Res. 2010;15 Suppl 2:83–7.PubMedCentralPubMed
78.
Despas F, Detis N, Dumonteil N, Labrunee M, Bellon B, Franchitto N, et al. Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation. J Hypertens. 2009;27(9):1849–54. doi:10.​1097/​HJH.​0b013e32832e8d0f​.PubMed
79.
80.
Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens. 2001;19(10):1713–6.PubMed
81.
Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763–78.PubMed
82.
83.
84.
Barajas L, Wang P. Myelinated nerves of the rat kidney. A light and electron microscopic autoradiographic study. J Ultrastruct Res. 1978;65(2):148–62.PubMed
85.
Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst. 1981;3(2–4):237–51.PubMed
86.
Donovan MK, Wyss JM, Winternitz SR. Localization of renal sensory neurons using the fluorescent dye technique. Brain Res. 1983;259(1):119–22.PubMed
87.
Solano-Flores LP, Rosas-Arellano MP, Ciriello J. Fos induction in central structures after afferent renal nerve stimulation. Brain Res. 1997;753(1):102–19.PubMed
88.
89.
Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26(5):861–5.PubMed
90.••
Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974–9. This fascinating clinical study demonstrated increased SNA despite correction of uremia in renal transplant recipients with diseased native kidneys, indicating a possible role for renal afferents in triggering heightened efferent sympathetic discharge.PubMed
91.
Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51(3):722–7.PubMed
92.
Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11(6 Pt 1):723–8.PubMed
93.
Katholi RE, Whitlow PL, Winternitz SR, Oparil S. Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension. Hypertension. 1982;4(3 Pt 2):166–74.PubMed
94.
Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17(6 Pt 2):1057–62.PubMed
95.
Fall PJ, Prisant LM. Polycystic kidney disease. J Clin Hypertens (Greenwich, Conn). 2005;7(10):617–9. 25.
96.
Costa F, Diedrich A, Johnson B, Sulur P, Farley G, Biaggioni I. Adenosine, a metabolic trigger of the exercise pressor reflex in humans. Hypertension. 2001;37(3):917–22.PubMed
97.
Chesterton LJ, Sigrist MK, Bennett T, Taal MW, McIntyre CW. Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrol Dial Transplant. 2005;20(6):1140–7.PubMed
98.
Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni I, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens. 2010;28(1):163–9. doi:10.​1097/​HJH.​0b013e328331b81e​.PubMed
99.
Ng K, Hildreth CM, Phillips JK, Avolio AP. Aortic stiffness is associated with vascular calcification and remodeling in a chronic kidney disease rat model. Am J Physiol Renal Physiol. 2011;300(6):6.
100.
Pai A, Leaf EM, El-Abbadi M, Giachelli CM. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol. 2011;178(2):764–73.PubMedCentralPubMed
101.
Chan CT, Jain V, Picton P, Pierratos A, Floras JS. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005;68(1):338–44. doi:10.​1111/​j.​1523-1755.​2005.​00411.​x.PubMed
102.
Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients. J Hypertens. 2002;20(3):501–8.PubMed
103.
Diwan V, Gobe G, Brown L. Glibenclamide improves kidney and heart structure and function in the adenine-diet model of chronic kidney disease. Pharmacol Res Off J Ital Pharmacol Soc. 2014;79:104–10. doi:10.​1016/​j.​phrs.​2013.​11.​007.
104.
Fedecostante M, Spannella F, Cola G, Espinosa E, Dessi-Fulgheri P, Sarzani R. Chronic kidney disease is characterized by “double trouble” higher pulse pressure plus night-time systolic blood pressure and more severe cardiac damage. PLoS One. 2014;9(1), e86155. doi:10.​1371/​journal.​pone.​0086155.PubMedCentralPubMed
105.
Wang AY, Li PK, Lui SF, Sanderson JE. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence? Nephrology (Carlton, Vic). 2004;9(4):190–7. doi:10.​1111/​j.​1440-1797.​2004.​00260.​x.
106.
Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54(6):505–12. doi:10.​1016/​j.​jacc.​2009.​03.​066.PubMed
107.
108.
Grassi G, Giannattasio C, Cleroux J, Cuspidi C, Sampieri L, Bolla GB, et al. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension. 1988;12(3):227–37.PubMed
109.
Uggere TA, Abreu GR, Sampaio KN, Cabral AM, Bissoli NS. The cardiopulmonary reflexes of spontaneously hypertensive rats are normalized after regression of left ventricular hypertrophy and hypertension. Braz J Med Biol Res Rev Bras Pesqui Med Biol Soc Bras Biofisica [et al]. 2000;33(5):589–94.
110.
Furchgott RF, Jothianandan D. Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels. 1991;28(1–3):52–61.PubMed
111.
Hirooka Y, Kishi T, Sakai K, Takeshita A, Sunagawa K. Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am J Physiol Regul Integr Comp Physiol. 2011;300(4):R818–26. doi:10.​1152/​ajpregu.​00426.​2010.PubMed
112.
Nurminen ML, Ylikorkala A, Vapaatalo H. Central inhibition of nitric oxide synthesis increases blood pressure and heart rate in anesthetized rats. Methods Find Exp Clin Pharmacol. 1997;19(1):35–41.PubMed
113.
Sakuma I, Togashi H, Yoshioka M, Saito H, Yanagida M, Tamura M, et al. NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? Circ Res. 1992;70(3):607–11.PubMed
114.
Cunha RS, Cabral AM, Vasquez EC. Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens. 1993;6(9):806–9.PubMed
115.
Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension. 1995;26(4):691–5.PubMed
116.
Harada S, Tokunaga S, Momohara M, Masaki H, Tagawa T, Imaizumi T, et al. Inhibition of nitric oxide formation in the nucleus tractus solitarius increases renal sympathetic nerve activity in rabbits. Circ Res. 1993;72(3):511–6.PubMed
117.
Zanzinger J, Czachurski J, Seller H. Inhibition of basal and reflex-mediated sympathetic activity in the RVLM by nitric oxide. Am J Physiol. 1995;268(4 Pt 2):R958–62.PubMed
118.
Zhang K, Mayhan WG, Patel KP. Nitric oxide within the paraventricular nucleus mediates changes in renal sympathetic nerve activity. Am J Physiol. 1997;273(3 Pt 2):R864–72.PubMed
119.
Spieker LE, Corti R, Binggeli C, Luscher TF, Noll G. Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans. J Am Coll Cardiol. 2000;36(1):213–8.PubMed
120.
121.
122.
Shinohara K, Hirooka Y, Kishi T, Sunagawa K. Reduction of nitric oxide-mediated gamma-amino butyric acid release in rostral ventrolateral medulla is involved in superoxide-induced sympathoexcitation of hypertensive rats. Circ J. 2012;76(12):2814–21.PubMed
123.
124.
125.
Matthews KA, Woodall KL, Allen MT. Cardiovascular reactivity to stress predicts future blood pressure status. Hypertension. 1993;22(4):479–85.PubMed
126.
Schuler JL, O'Brien WH. Cardiovascular recovery from stress and hypertension risk factors: a meta-analytic review. Psychophysiology. 1997;34(6):649–59.PubMed
127.
128.
Niebylski A, Boccolini A, Bensi N, Binotti S, Hansen C, Yaciuk R, et al. Neuroendocrine changes and natriuresis in response to social stress in rats. Stress Health J Int Soc Investig Stress. 2012;28(3):179–85. doi:10.​1002/​smi.​1411.
129.
Wallin BG, Esler M, Dorward P, Eisenhofer G, Ferrier C, Westerman R, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol. 1992;453:45–58.PubMedCentralPubMed
130.
Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16(6):622–53.PubMed
131.
Kouidi E, Karagiannis V, Grekas D, Iakovides A, Kaprinis G, Tourkantonis A, et al. Depression, heart rate variability, and exercise training in dialysis patients. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol. 2010;17(2):160–7. doi:10.​1097/​HJR.​0b013e32833188c4​.
132.
Palkovits M, Sebekova K, Klenovics KS, Kebis A, Fazeli G, Bahner U, et al. Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine. PLoS One. 2013;8(6), e66543. doi:10.​1371/​journal.​pone.​0066543.PubMedCentralPubMed
133.
Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther. 2006;23(6):988–98.PubMed
134.
135.
Hall JE, Brands MW, Zappe DH, Alonso Galicia M. Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med Soc Exp Biol Med (New York, NY). 1995;208(4):317–29.
136.
137.
Schneider MP, Mann JF. Endothelin antagonism for patients with chronic kidney disease: still a hope for the future. Nephrol Dial Transplant. 2014;29 Suppl 1:i69–73. doi:10.​1093/​ndt/​gft339.PubMed
138.
Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990;15(5):493–6.PubMed
139.
Gulati A, Rebello S, Kumar A. Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am J Physiol. 1997;273(3 Pt 2):H1177–86.PubMed
140.
Nakamura K, Sasaki S, Moriguchi J, Morimoto S, Miki S, Kawa T, et al. Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. J Cardiovasc Pharmacol. 1999;33(6):876–82.PubMed
141.
Mortensen LH. Endothelin and the central and peripheral nervous systems: a decade of endothelin research. Clin Exp Pharmacol Physiol. 1999;26(12):980–4.PubMed
142.
Smirnov AV, Petrishchev NN, Panina I, Mnuskina MM, Achkasova VV, Rumiantsev A, et al. The level of endothelin-1 and reactivity of skin microvessels in patients with early stages of chronic kidney disease. Ter Arkh. 2011;83(6):13–8.PubMed
143.
Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–80. doi:10.​1172/​jci24066.PubMedCentralPubMed
144.
145.
146.
147.
148.
Mailloux LU. The overlooked role of salt restriction in dialysis patients. Semin Dial. 2000;13(3):150–1.PubMed
149.
150.
Campese VM, Mozayeni P, Ye S, Gumbard M. High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol. 2002;15(4):407–13.PubMed
151.
Fujita M, Ando K, Kawarazaki H, Kawarasaki C, Muraoka K, Ohtsu H, et al. Sympathoexcitation by brain oxidative stress mediates arterial pressure elevation in salt-induced chronic kidney disease. Hypertension. 2012;59(1):105–12. doi:10.​1161/​hypertensionaha.​111.​182923.PubMed
152.
Wambach G, Gotz S, Suckau G, Bonner G, Kaufmann W. Plasma levels of atrial natriuretic peptide are raised in essential hypertension during low and high sodium intake. Klin Wochenschr. 1987;65(5):232–7.PubMed
153.
Akiba T, Tachibana K, Togashi K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44 Suppl 1:S61–4.PubMed
154.
Peng N, Oparil S, Meng QC, Wyss JM. Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats. J Clin Investig. 1996;98(9):2060–5. doi:10.​1172/​jci119011.PubMedCentralPubMed
155.
Vatta MS, Papouchado ML, Bianciotti LG, Fernandez BE. Atrial natriuretic factor inhibits noradrenaline release in the presence of angiotensin II and III in the rat hypothalamus. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1993;106(2):545–8.
156.
Toader E, McAllen RM, Cividjian A, Woods RL, Quintin L. Effect of systemic B-type natriuretic peptide on cardiac vagal motoneuron activity. Am J Physiol Heart Circ Physiol. 2007;293(6):H3465–70. doi:10.​1152/​ajpheart.​00528.​2007.PubMed
157.
Woods RL, Courneya CA, Head GA. Nonuniform enhancement of baroreflex sensitivity by atrial natriuretic peptide in conscious rats and dogs. Am J Physiol. 1994;267(3 Pt 2):R678–86.PubMed
158.
159.
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988–1991. Hypertension. 1995;25(3):305–13.PubMed
160.
161.
Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37(5):1199–208.PubMed
162.
Hogarth AJ, Mackintosh AF, Mary DA. Gender-related differences in the sympathetic vasoconstrictor drive of normal subjects. Clin Sci. 2007;112(6):353–61.PubMed
163.
Kim A, Deo SH, Vianna LC, Balanos GM, Hartwich D, Fisher JP, et al. Sex differences in carotid baroreflex control of arterial blood pressure in humans: relative contribution of cardiac output and total vascular conductance. Am J Physiol Heart Circ Physiol. 2011;301(6):H2454–65.PubMedCentralPubMed
164.
Shoemaker JK, Hogeman CS, Khan M, Kimmerly DS, Sinoway LI. Gender affects sympathetic and hemodynamic response to postural stress. Am J Physiol Heart Circ Physiol. 2001;281(5):H2028–35.PubMed
165.
Tank J, Diedrich A, Szczech E, Luft FC, Jordan J. Baroreflex regulation of heart rate and sympathetic vasomotor tone in women and men. Hypertension. 2005;45(6):1159–64.PubMed
166.
Brooks VL, Cassaglia PA, Zhao D, Goldman RK. Baroreflex function in females: changes with the reproductive cycle and pregnancy. Gend Med. 2012;9(2):61–7.PubMedCentralPubMed
167.
Abdel-Rahman AR, Merrill RH, Wooles WR. Gender-related differences in the baroreceptor reflex control of heart rate in normotensive humans. J Appl Physiol (Bethesda, Md : 1985). 1994;77(2):606–13.
168.
Frey MA, Tomaselli CM, Hoffler WG. Cardiovascular responses to postural changes: differences with age for women and men. J Clin Pharmacol. 1994;34(5):394–402.PubMed
169.
Convertino VA. Gender differences in autonomic functions associated with blood pressure regulation. Am J Physiol. 1998;275(6 Pt 2):R1909–20.PubMed
170.
Scislo TJ, DiCarlo SE. Gender difference in cardiopulmonary reflex inhibition of sympathetic nerve activity. Am J Physiol. 1994;267(4 Pt 2):H1537–43.PubMed
171.
Hunt BE, Taylor JA, Hamner JW, Gagnon M, Lipsitz LA. Estrogen replacement therapy improves baroreflex regulation of vascular sympathetic outflow in postmenopausal women. Circulation. 2001;103(24):2909–14.PubMed
172.
Fadel PJ, Zhao W, Thomas GD. Impaired vasomodulation is associated with reduced neuronal nitric oxide synthase in skeletal muscle of ovariectomized rats. J Physiol. 2003;549(Pt 1):243–53.PubMedCentralPubMed
173.
Mohamed MK, El-Mas MM, Abdel-Rahman AA. Estrogen enhancement of baroreflex sensitivity is centrally mediated. Am J Physiol. 1999;276(4 Pt 2):R1030–7.PubMed
174.
Saleh TM, Connell BJ. 17beta-estradiol modulates baroreflex sensitivity and autonomic tone of female rats. J Auton Nerv Syst. 2000;80(3):148–61.PubMed
175.
Du XJ, Dart AM, Riemersma RA. Sex differences in the parasympathetic nerve control of rat heart. Clin Exp Pharmacol Physiol. 1994;21(6):485–93.PubMed
176.
Schroeder C, Adams F, Boschmann M, Tank J, Haertter S, Diedrich A, et al. Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol. 2004;286(5):R851–6.PubMed
177.
Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70(4):963–85.PubMed
178.
Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension. 2000;35(1 Pt 2):480–3.PubMed
179.
Crofton JT, Ota M, Share L. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J Hypertens. 1993;11(10):1031–8.PubMed
180.
Haywood JR, Hinojosa-Laborde C. Sexual dimorphism of sodium-sensitive renal-wrap hypertension. Hypertension. 1997;30(3 Pt 2):667–71.PubMed
181.
182.
183.
Pavithran P, Madanmohan T, Nandeesha H. Sex differences in short-term heart rate variability in patients with newly diagnosed essential hypertension. J Clin Hypertens. 2008;10(12):904–10.
184.
Johnson MS, DeMarco VG, Heesch CM, Whaley-Connell AT, Schneider RI, Rehmer NT, et al. Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2011;301(4):H1540–50.PubMedCentralPubMed
185.
Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69(2):375–82. doi:10.​1038/​sj.​ki.​5000058.PubMed
186.
Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant. 2003;18(10):2047–53. doi:10.​1093/​ndt/​gfg317.PubMed
187.
Carrero JJ. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res. 2010;33(5):383–92. doi:10.​1159/​000320389.PubMed
188.
Vink EE, de Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep. 2013;15(2):95–101. doi:10.​1007/​s11906-013-0328-5.PubMed
189.
190.
191.
Sato R, Mizuno M, Miura T, Kato Y, Watanabe S, Fuwa D, et al. Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure. J Hypertens. 2013;31(6):1233–8. doi:10.​1097/​HJH.​0b013e32836043c9​.PubMed
192.
Ondocin PT, Narsipur SS. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology (Carlton, Vic). 2006;11(6):497–501. doi:10.​1111/​j.​1440-1797.​2006.​00680.​x.
193.•
Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15(11):2902–7. doi:10.​1097/​01.​asn.​0000143471.​10750.​8c. This clinical study showed that normalized sympathetic nerve discharge in CKD patients can be achieved only with combination therapy comprising a central sympatholytic agent and an ARB.PubMed
194.
Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(9):2930–4. doi:10.​1093/​ndt/​gfq857.PubMed
195.
Narsipur SS, Srinivasan B, Singh B. Effect of simvastatin use on autonomic function in patients with end stage renal disease. Cardiovasc Hematol Disord Drug Targets. 2011;11(1):53–7.PubMed
196.
Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, Okada H, Chen XM. Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report. Hypertens Res Off J Jpn Soc Hypertens. 2001;24(2):153–8.
197.
198.
199.
Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11(8):1469–78.PubMed
200.
201.
Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–44.PubMed
202.
203.
Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984;6(4):557–62.PubMed
204.
205.
Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4.PubMed
206.
Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006;17(4 Suppl 2):S98–103. doi:10.​1681/​asn.​2005121319.PubMed
207.
Kiuchi MG, Maia GL, de Queiroz Carreira MA, Kiuchi T, Chen S, Andrea BR, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34(28):2114–21. doi:10.​1093/​eurheartj/​eht200.PubMed
208.
Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457–64. doi:10.​1161/​hypertensionaha.​111.​00194.PubMed
209.
Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60(6):1485–90. doi:10.​1161/​hypertensionaha.​112.​201186.PubMed
210.
Hart EC, McBryde FD, Burchell AE, Ratcliffe LE, Stewart LQ, Baumbach A, et al. Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans. Hypertension. 2013;62(3):533–41. doi:10.​1161/​hypertensionaha.​113.​01261.PubMed
211.
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. doi:10.​1056/​NEJMoa1402670.PubMed
212.
213.
214.
Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619–26. doi:10.​1161/​hypertensionaha.​109.​140665.PubMed
215.
216.
Goddard J, Turner AN. Kidney and urinary tract disease. In: Walker BR, Colledge NR, Ralston SH, Penman ID, editors. Davidson's principles and practice of medicine. 22nd ed. Philadelphia: Churchill Livingstone Elsevier; 2014.
217.
Chesterton LJ, Selby NM, Burton JO, Fialova J, Chan C, McIntyre CW. Categorization of the hemodynamic response to hemodialysis: the importance of baroreflex sensitivity. Hemodial Int Int Symp Home Hemodial. 2010;14(1):18–28. doi:10.​1111/​j.​1542-4758.​2009.​00403.​x.
218.
Giordano M, Manzella D, Paolisso G, Caliendo A, Varricchio M, Giordano C. Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant. 2001;16(3):566–73.PubMed
219.
Mylonopoulou M, Tentolouris N, Antonopoulos S, Mikros S, Katsaros K, Melidonis A, et al. Heart rate variability in advanced chronic kidney disease with or without diabetes: midterm effects of the initiation of chronic haemodialysis therapy. Nephrol Dial Transplant. 2010;25(11):3749–54. doi:10.​1093/​ndt/​gfq226.PubMed
220.
Chan CT, Chertow GM, Daugirdas JT, Greene TH, Kotanko P, Larive B, et al. Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) daily trial. Nephrol Dial Transplant. 2014;29(1):168–78. doi:10.​1093/​ndt/​gft212.PubMedCentralPubMed
221.
222.
Korejwo G, Hermann A, Zdrojewski Z, Debska-Slizien A, Rutkowski B. Improved autonomic function after kidney transplantation. Transplant Proc. 2002;34(2):601–3.PubMed
223.
224.
Heidbreder E, Schafferhans K, Heidland A. Disturbances of peripheral and autonomic nervous system in chronic renal failure: effects of hemodialysis and transplantation. Clin Nephrol. 1985;23(5):222–8.PubMed
Metadata
Title
Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review
Author
Ibrahim M. Salman
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 8/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0571-z

Other articles of this Issue 8/2015

Current Hypertension Reports 8/2015 Go to the issue

Pulmonary Hypertension (JR Klinger, Section Editor)

Management of Pulmonary Hypertension in Patients with Chronic Lung Disease

Preeclampsia (VD Garovic, Section Editor)

Cerebrovascular Dysfunction in Preeclamptic Pregnancies

Novel Treatments for Hypertension (T Unger, Section Editor)

Does Measurement of Central Blood Pressure have Treatment Consequences in the Clinical Praxis?

Preeclampsia (VD Garovic, Section Editor)

Preeclampsia: What Does the Father Have to Do with It?

Resistant Hypertension (E Pimenta, Section Editor)

Quality of Life in Treatment-Resistant Hypertension

Novel Treatments for Hypertension (T Unger, Section Editor)

Treating Hypertension in Pregnancy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits